Literature DB >> 15701441

Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia.

Michael J Mann1, Elaine Tseng, Mark Ratcliffe, Greg Strattman, Anil De Silva, Teresa Demarco, Nancy Achorn, William Moskalik, Charles Hoopes.   

Abstract

Heparin-induced thrombocytopenia (HIT) is an increasingly common clinical finding in patients presenting for cardiac transplantation. Bivalrudin, a reversible direct thrombin inhibitor, is a molecular anti-coagulant with short half-life and the potential for removal by intraoperative hemofiltration. Herein we describe the dosing and intraoperative management of bivalrudin anti-coagulation in a patient undergoing urgent cardiac transplantation in the context of recently diagnosed HIT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15701441     DOI: 10.1016/j.healun.2003.11.401

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  6 in total

1.  Bivalirudin Medication Use Evaluation and Cost Savings Initiative.

Authors:  Adam C Sieg; Jennifer A Gass
Journal:  Hosp Pharm       Date:  2017-07-25

Review 2.  Heparin-induced thrombocytopenia in solid organ transplant recipients: The current scientific knowledge.

Authors:  Volker Assfalg; Norbert Hüser
Journal:  World J Transplant       Date:  2016-03-24

Review 3.  Direct thrombin inhibitors: pharmacology and application in intensive care medicine.

Authors:  Eva Schaden; Sibylle A Kozek-Langenecker
Journal:  Intensive Care Med       Date:  2010-04-28       Impact factor: 17.440

Review 4.  Heparin induced thrombocytopenia in critically ill: Diagnostic dilemmas and management conundrums.

Authors:  Sachin Gupta; Ravindranath Tiruvoipati; Cameron Green; John Botha; Huy Tran
Journal:  World J Crit Care Med       Date:  2015-08-04

Review 5.  [Direct thrombin inhibitors: pharmacology and application in cardiovascular anesthesia].

Authors:  S A Kozek-Langenecker
Journal:  Anaesthesist       Date:  2008-06       Impact factor: 1.041

Review 6.  Antiphospholipid syndrome; its implication in cardiovascular diseases: a review.

Authors:  Ioanna Koniari; Stavros N Siminelakis; Nikolaos G Baikoussis; Georgios Papadopoulos; John Goudevenos; Efstratios Apostolakis
Journal:  J Cardiothorac Surg       Date:  2010-11-03       Impact factor: 1.637

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.